




Figura

<https://doi.org/10.1016/j.aohep.2024.101676>

P-63 CHARACTERISTICS AND CLINICAL OUTCOMES IN CIRRHOTIC PATIENTS TREATED IN ICU BETWEEN 2018-2023

Daniel Rojas Kozhakin¹, Juan Linares¹,
Maria Rincon¹, Angelica Sanabria¹,
Adriana Varon Puerta¹

¹ La Cardio, Bogotá, Colombia

Conflict of interest: No

Introduction and Objectives: Cirrhosis is a chronic disease with a variable clinical course ranging from compensated stage to acute-on-chronic liver failure. The management of such patients focuses on multiorgan support in the intensive care unit (ICU). However, the criteria for defining the futility of management or even potential candidates for transplantation in our setting are not clearly established. **Objectives:** To describe the sociodemographic and clinical characteristics and outcomes of adult patients with liver cirrhosis treated in the ICU between 2018 and 2023 at the Cardioinfantil Foundation.

Patients / Materials and Methods: A retrospective observational cohort study was conducted. Quantitative variables were described as mean and standard deviation or median and interquartile range, depending on their distribution. Qualitative variables were expressed as frequencies and percentages. To compare variables between groups, Student's t tests were used for continuous variables and chi-square tests or Fisher's exact test for categorical variables. Logistic regression models were applied to identify risk factors associated with mortality, adjusting for possible confounders.

Results and Discussion: Statistically significant differences ($p<0.001$) were found associated with higher mortality in patients with higher CHILD, MELD and CLIF-C AD scores. Higher mortality was also found in patients with associated renal dysfunction, who developed any type of infection or who required IMV. No differences in survival were found in patients who underwent transplantation.

Conclusions: Patients with cirrhosis treated in the ICU have a higher mortality rate in relation to greater renal dysfunction, need for IVM, impaired hepatic synthesis or the presence of any type of infection. Respiratory and urinary tract infection were the most common. No association was found with systemic inflammatory

response and mortality. The proportion of suitable patients eligible for transplant was low. Prospective studies are required to identify the patient population that may benefit from early transplantation and thereby improve their survival.




Table 1. Demographic and clinical characteristics and risk markers			
	Total population n= 121	Dead n= 35	p Value
Age, median (IQR)	60.00 [52.00, 64.00]	61.00 [52.25, 65.00]	0.054
CHILD, median (IQR)	11.00 [9.00, 12.00]	11.00 [10.00, 12.00]	<0.001
MELD, median (IQR)	20.00 [16.00, 26.00]	22.00 [18.25, 28.00]	<0.001
MELD Na, median (IQR)	23.00 [18.00, 30.00]	19.00 [13.00, 23.00]	<0.001
CLIF_C AD, median (IQR)	56.00 [50.75, 66.00]	52.00 [46.00, 56.00]	0.001
Creatinine, median (IQR)	1.20 [0.80, 2.00]	1.30 [0.90, 2.18]	<0.001
Infection (%)	85 (70.2)	17 (48.6)	0.002
Transplant (%)	11 (9.1%)	7 (20%)	0.016
HRS, n (%)	66 (54.5)	4 (11.4)	<0.001
IMV, n (%)	29 (24.0)	25 (29.1)	<0.001

Table 1. Patient Characteristics

<https://doi.org/10.1016/j.aohep.2024.101677>

P-64 DOWNSTAGING STRATEGY FOR LIVER TRANSPLANTATION IN HEPATOCELLULAR CARCINOMA. A COHORT STUDY IN A COLOMBIAN HOSPITAL

Juan Ignacio Marin-Zuluaga¹,
Andres Fernando Rodriguez-Gutierrez²,
María Fernanda Saavedra-Chacón²,
Christian Ernesto Melgar-Burbano²

¹ Hospital Pablo Tobón Uribe, Medellín, Colombia
² Universidad de Antioquia, Medellín, Colombia

Conflict of interest: No


Introduction and Objectives: Hepatocellular carcinoma (HCC) with low tumor burden can be treated by liver transplantation (LT). Downstaging is a strategy to reduce tumor burden and allow transplantation. **Objectives:** To present the features and outcomes of patients undergoing LT with a downstaging and to compare them with patients transplanted according to Milan criteria

Patients / Materials and Methods: Retrospective cohort study of transplanted patients from July 2012 to January 2024 in a Colombian hospital. Downstaging was carried out in accordance with UNOS criteria. Death and recurrence of HCC were the primary outcomes. Cox proportional hazards model was adjusted for age and Child-Pugh score.

Results and Discussion: 79 patients, 17 in downstaging group (DG) and 62 in Milan Group (MG). All patients had cirrhosis. Median age was 60 years and 71% were men. DG has less diabetes mellitus than MG (24% vs. 48%), less comorbidities (82% vs. 92%), better Child-Pugh, less ascites (6% vs. 50%), less encephalopathy (18% vs. 45%) and less variceal bleeding (17% vs. 32%). In DG, the median number of tumors was 2 (IQR: 1-3, 29% with just one) and in MG it was 1 (IQR: 1-1, 79% with just one). Downstaging was performed using either TACE alone (88%) or in combination with radiofrequency ablation (22%). Liver specimens showed a high sum of tumor diameters in DG

(4.8 cm vs. 3.0 cm), however, DG had less microvascular invasion (18% vs. 37%) and a better profile of tumor differentiation. Recurrence was 11.8% in DG and 8.2% in MG (p-value = 0.926, figure). In DG, there was a death rate of 6% while in MG it was 18% (p-value = 0.285).

Conclusions: Downstaging appeared to be a successful strategy for LT that could be used to expand the Milan Criteria in Colombia. Less sick patients in DG (necessary for locoregional therapy), could have favored survival.



<https://doi.org/10.1016/j.aohep.2024.101678>

P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Issac Octavio Vargas Olmos¹,
Graciela Elia Castro Narro¹, Aldo Torre Delgadillo²,
Jose Antonio Cienfuegos Alvear³,
Elsie Daniela Sánchez Sánchez⁴

¹ Departamento Gastroenterología - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México

² Gastroenterología - American British Cowdray Medical Center, Ciudad de México, México

³ Departamento Radiología - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México

⁴ Medicina Interna - American British Cowdray Medical Center, Ciudad de México, México

Conflict of interest: No

Introduction and Objectives: Thrombosis of the portal venous (PVT) system is a frequent and potentially life-threatening condition in patients with liver disease. Percutaneous interventional procedures have gained worldwide acceptance for alleviating the symptoms of portal hypertension.

The objective of this study is to evaluate the impact of portal plasty on patients with decompensated cirrhosis and to analyze the correlations between different prognostic scales, laboratory and imaging results to determine the postoperative prognosis in these patients.

Patients / Materials and Methods: We included 13 patients with liver cirrhosis and chronic portal thrombosis with portal plasty ± TIPS. Data collection tools involved reviewing the clinical histories of the patients to obtain necessary data such as platelets, sodium, liver function tests, and findings via tomography to evaluate ascites and splenomegaly. Calculation tools from Stanford University were used to determine MELD, MELD Na, and MELD 3.0 scores. Finally, a descriptive analysis was performed for all collected variables. Descriptive statistics were analyzed using means for continuous variables.

Results and Discussion: Patients with portal plasty had the following outcomes at 3 months: delta MELD-Sodium -1.2 points, which paralleled an improvement in sodium levels with a delta +2.4 meq/L. This could be due to the improvement of the hypervolemic state, 100% of the patients presented some degree of improvement in ascites as assessed by abdominal tomography.

The platelet count presented a delta of +16,000 platelets, reflecting an improvement of portal hypertension and splenomegaly.

The small decrease in MELD 3.0 can be explained by the improvement in serum albumin levels by 0.8 g/dL, which could reflect less inflammation in patients with chronic thrombosis. There was no significant difference in Child Pugh, hemoglobin, creatinine, bilirubin and coagulation tests.

Two patients were included in the transplant list and were transplanted successfully.

Conclusions: Portal plasty ± TIPS in patients with cirrhosis and chronic thrombosis is a viable treatment with clinical and biochemical benefits, with minimal adverse effects, which can be used as a bridging therapy for liver transplantation.



Portal Plasty

Outcome	Mean 3 months delta
MELD-Na	-1.2 points
MELD 3.0	-0.9 points
Sodium	+2.4 meq/L
Platelets	+16,000 /L
Albumin	+0.8 gr/dl
Hemoglobin	+0.7 mg/dl
Creatinine	-0.1 mg/dl
INR	-0.2
Total Bilirubin	-0.3 mg/dl
Child Pugh	-0.2 points

Clinical and biochemical outcomes

<https://doi.org/10.1016/j.aohep.2024.101679>